Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Spero Therapeutics Inc (SPRO – Research Report) today and set a price target of $27. The company’s shares opened today at $9.18, close to its 52-week low of $7.80.
“. Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts for the rest of 2018+.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 17.6% and a 45.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on Spero Therapeutics Inc is a Moderate Buy with an average price target of $23.25, which is a 153.3% upside from current levels. In a report issued on October 26, Cowen & Co. also maintained a Buy rating on the stock.
The company has a one-year high of $19 and a one-year low of $7.80. Currently, Spero Therapeutics Inc has an average volume of 102.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206.